Pamisel Signs Business Agreement with Soonchunhyang University Seoul Hospital
[Asia Economy Reporter Hyungsoo Park] Pharmicell is taking steps to promote regenerative medicine research and expand the attraction of foreign patients.
Pharmicell announced on the 22nd that it has signed a business agreement with Soonchunhyang University Seoul Hospital for regenerative medicine research and medical tourism.
According to the agreement, both parties will utilize their capabilities and resources to operate a platform for attracting foreign patients and aim to revitalize medical tourism services through the establishment of a medical treatment system.
They will research customized treatment technologies that can predict treatment outcomes using stem cells by analyzing stem cell big data and genetic sequences. In addition, they will conduct ▲development of raw materials necessary for genetic analysis ▲preclinical and clinical research ▲new drug development research, among others.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Pharmicell is currently conducting a Phase 3 clinical trial of the stem cell therapy Cellgram-LC on 200 patients with alcoholic liver cirrhosis at Soonchunhyang University Seoul Hospital and 10 other institutions.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
